Medical device mergers on pause

2019 was an average year for medtech M&A. 2020, not so much.

Thanks to Thermo Fisher Scientific and Invitae, two groups brave enough to push ahead with multibillion-dollar acquisitions during a pandemic, the total value of medical device M&A announced in the first half of 2020 nudged over $15bn. This is still a distressingly low figure, however the real shock is not the value of the deals announced, but of those that have closed.

The medtech deals completed so far in 2020 have a total value of less than $2bn. This is despite mergers worth a total of more than $21bn remaining open. The Covid-19 pandemic seems to have made it harder to hammer out the legal or financial complications of closing deals than it did to conduct the negotiations in the first place.

Of course, the pandemic is not the only element at play. The largest pending deal is Stryker’s $11.5bn purchase of Wright Medical, which was announced in November but has since run into trouble with the US Federal Trade Commission and the UK’s Competition and Markets Authority. Given that last December the FTC scuttled Illumina’s proposed $1.2bn acquisition of Pacific Biosciences, this is a serious threat.

Investors however have shaken off concerns, with Wright’s share price trading just below the acquisition price of $30.75. The deal was not expected to close until the latter half of 2020 anyway. It might still meet this schedule, thus boosting 2020’s numbers, but the involvement of the antitrust watchdogs mean this cannot be relied on.

Partly owing to the lack of this deal, the average size of completed mergers is lower than at any point in the past decade. The mean acquisition size was just $108m in the first six months of 2020; this figure has been erratic over the past 10 years but shows an overall downturn since 2015.

It is also interesting that the two big acquisitions announced so far in 2020 are both diagnostics deals. The unveiling of the $11.5bn Thermo Fisher-Qiagen deal predates the WHO’s designation of Covid-19 as a pandemic, and thus the deal has little to do with tests for the coronavirus itself – though Qiagen has subsequently developed and launched Covid-19 tests.

By Elizabeth Cairns | Evaluate

Image Credit: Elizabeth Cairns / Evaluate

READ MORE

Avatar
About Peter Coffaro 782 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the orthopedic industry. Recognized by MedReps.com as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager and Distributor. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy and Stryker. He is also the founder of OrthoFeed: a popular blog that covers orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing and professional education. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.